Sign in
ZEAL Stock Price, Chart, Stats & News
Zealand Pharma A/S
Save
Zealand Pharma A/S (ZEAL) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
ZEAL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 59.39% |
Operating margin | -349.61% |
Pretax margin | -351.01% |
Net margin | -348.01% |
Effective tax rate | 0.86% |
ROA | -49.24% |
ROE | -96.74% |
D/E | 0.85x |
Interest coverage ratio | -250.02x |
ZEAL valuation
P/E | – |
P/S | – |
P/B | 4.72x |
P/CF | -3.61x |
P/FCF | – |
P/OCF | -3.61x |
PEG | -0.01x |
EV multiple | -0.35x |
About
Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S is a biotechnology firm focused on the discovery, development, and commercialization of peptide-based medications. The company's therapeutic pipeline and marketed products primarily address gastrointestinal and metabolic diseases, as well as other niche conditions with significant unmet medical needs. Currently, Zealand Pharma markets lixisenatide under the brand names Adlyxin and Lyxumia.
Similar securities
Based on sector and market capitalization
Report issue